BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dravet Syndrome readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Dravet Syndrome\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06872125-9001@assetmemo.bio
DTSTAMP:20261121T004951Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Zorevunersen: Phase 3 readout est. (NCT06872125)
DESCRIPTION:Zorevunersen\, phase 3\, Dravet Syndrome.\nStudy: A Double-blin
 d Study Evaluating the Efficacy\, Safety\, and Tolerability of Zorevunerse
 n in Patients With Dravet Syndrome\nEstimated primary completion: March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/zorevunersen#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06872125
URL:https://assetmemo.bio/drug/zorevunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462770-8988@assetmemo.bio
DTSTAMP:20261121T004951Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Clemizole (EPX-100): Phase 3 readout est. (NCT04462770)
DESCRIPTION:Clemizole (EPX-100)\, phase 3\, Epilepsy.\nStudy: A Study of EP
 X-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/clemizole-epx-100#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04462770
URL:https://assetmemo.bio/drug/clemizole-epx-100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04740476-9001@assetmemo.bio
DTSTAMP:20261121T004951Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zorevunersen: Phase 2 readout est. (NCT04740476)
DESCRIPTION:Zorevunersen\, phase 2\, Dravet Syndrome.\nStudy: An Open-Label
  Extension Study of STK-001 for Patients With Dravet Syndrome\nEstimated p
 rimary completion: 31 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zorevunersen#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04740476
URL:https://assetmemo.bio/drug/zorevunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
